In human cancer cell-lines with defective function of BRCA1, PALB2 or BRCA2, RAD52′s depletion increases damage-associated chromosomal abnormalities, decreases clonal viability, and also reduces the HR activity [28,30]. The gene discussed is RAD52; the disease is cancer.